Primaquine
- Atc Codes:P01BA03
- CAS Codes:63-45-6#90-34-6
- PHARMGKB ID:63-45-6#90-34-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Primaquine; Italy: Primachina.
North America
Canada: Primaquine; USA: Primaquine.
Latin America
Brazil: Primakinder.
Drug combinations
Chemistry
Primaquine Phosphate: C~15~H~21~N~3~O 2H~3~PO~4~. Mw: 455.34. (1) 1,4-Pentanediamine, N^4^-(6-methoxy-8-quinolinyl)-, (±)-, phosphate (1:2); (2)(±)-8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline phosphate (1:2). CAS-63-45-6; CAS-90-34-6 (primaquine).
Pharmacologic Category
Antiprotozoals; Antimalarials. (ATC-Code: P01BA03).
Mechanism of action
Eliminates primary tissue exoerythrocytic forms of P. falciparum. Disrupts mitochondria and binds to DNA.
Therapeutic use
Prevention of relapse of P. vivax malaria.
Pregnancy and lactiation implications
Use caution during pregnancy or lactation.
Unlabeled use
Prevention of relapse of P. ovale malaria. Treatment of Pneumocystis jiroveci pneumonia. Prevention of chloroquine-resistant malaria.
Contraindications
Use in acutely-ill patients with tendency to develop granulocytopenia (e.g. rheumatoid arthritis, systemic lupus erythematosus). Concurrent use with other medications causing hemolytic anemia or myeloid bone marrow suppression. Concurrent or recent use of quinacrine. Contraindicated in patients receiving clozapine or carbamazepine.
Warnings and precautions
Hemolytic anemia (darkening of urine, marked fall in hemoglobin or erythrocyte count). Moderate-to-severe hemolytic reactions may occur in G6PD deficiency and personal or familial history of favism. Other hematologic effects (anemia, methemoglobinemia, and leukopenia) associated with primaquine use. Use with caution in known G6PD deficiency (use of aminoquinolines has been associated with hemolysis), and in NADH methemoglobin reductase deficiency (methemoglobinemia may occur).